Buchumschlag

Asprosin response in hypoglycemia is not related to hypoglycemia unawareness but rather to insulin resistance in type 1 diabetes

Asprosin is a counter-regulatory hormone to insulin which plays a role in fasting. It may therefore also play a role in hypoglycaemia unawareness, which has been subsequently examined in this pilot study. Intravenous glucose tolerance test was used to induce controlled hyperglycemia whereas a hyperi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Gröner, Jan (VerfasserIn) , Valkanou, Aikaterini (VerfasserIn) , Kender, Zoltán (VerfasserIn) , Pfeiffenberger, Jan (VerfasserIn) , Kihm, Lars Philipp (VerfasserIn) , Fleming, Thomas (VerfasserIn) , Nawroth, Peter Paul (VerfasserIn) , Kopf, Stefan (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: September 19, 2019
In: PLOS ONE
Year: 2019, Jahrgang: 14, Heft: 9
ISSN:1932-6203
DOI:10.1371/journal.pone.0222771
Online-Zugang:lizenzpflichtig
lizenzpflichtig
Volltext
Verfasserangaben:Jan Benedikt Groener, Aikaterini Valkanou, Zoltan Kender, Jan Pfeiffenberger, Lars Kihm, Thomas Fleming, Peter Paul Nawroth, Stefan Kopf
Beschreibung
Zusammenfassung:Asprosin is a counter-regulatory hormone to insulin which plays a role in fasting. It may therefore also play a role in hypoglycaemia unawareness, which has been subsequently examined in this pilot study. Intravenous glucose tolerance test was used to induce controlled hyperglycemia whereas a hyperinsulinemic clamp test was used to induce a controlled hypoglycaemia in 15 patients with diabetes type 1, with and without hypoglycaemia unawareness. Changes in asprosin plasma levels did not differ between patients with and without hypoglycaemia unawareness. However, nine patients with insulin resistance as well as higher liver stiffness values and low-density lipoprotein but lower high-density lipoprotein levels did not show the expected increase in asprosin plasma levels during hypoglycemia. Therefore, insulin resistance and alterations in liver structure, most likely early stages of non-alcoholic fatty liver disease, seem to be relevant in type 1 diabetes and do not only lead to elevated plasma levels of asprosin, but also to a blunted asprosin response in hypoglycemia.
Beschreibung:Gesehen am 23.04.2020
Beschreibung:Online Resource
ISSN:1932-6203
DOI:10.1371/journal.pone.0222771

Ähnliche Einträge